Skip to main content
Top

29-02-2024 | Type 1 Diabetes | Case Report

Type 1 diabetes mellitus following COVID-19 vaccination: a report of two cases and review of literature

Authors: Shota Mochizuki, Junnosuke Miura, Kiwako Ucida, Ryo Kubota, Hirona Fujikawa, Satoshi Takagi, Naoshi Yoshida, Sachiko Ootake, Chika Fujimori, Akihito Shinohara, Junji Tanaka, Tetsuya Babazono

Published in: Diabetology International

Login to get access

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection, which led to the coronavirus 2019 (COVID-19) pandemic, has promoted the development of novel therapeutic agents and vaccines to combat the global spread of the virus. While the COVID-19 vaccines approved thus far have proven to be effective in clinical settings, there have been reports of autoimmune diseases occurring following vaccination, including autoimmune/inflammatory syndrome induced by adjuvant syndrome. We herein report two cases of type 1 diabetes mellitus that occurred following COVID-19 vaccination and provide a literature review. Both cases received multiple vaccinations as recommended to ensure optimal antibody titers. Moreover, the HLA associated with susceptibility to type 1 diabetes was prototypic in both cases. This indirect evidence suggests that the COVID-19 vaccines may be implicated in the pathogenesis of type 1 diabetes. Further case reports to establish a clearer understanding of a potential association are warranted.
Appendix
Available only for authorised users
Literature
2.
go back to reference Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel). 2021;9:467.PubMedCrossRef Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel). 2021;9:467.PubMedCrossRef
3.
go back to reference Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, Medina G, Sánchez Valadez TI, et al. Two cases of Graves’ disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid. 2021;31:1436–9.PubMedCrossRef Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, Medina G, Sánchez Valadez TI, et al. Two cases of Graves’ disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid. 2021;31:1436–9.PubMedCrossRef
5.
go back to reference Das L, Bhadada SK, Sood A. Post-COVID-vaccine autoimmune/inflammatory syndrome in response to adjuvants (ASIA syndrome) manifesting as subacute thyroiditis. J Endocrinol Invest. 2022;45:465–7.PubMedCrossRef Das L, Bhadada SK, Sood A. Post-COVID-vaccine autoimmune/inflammatory syndrome in response to adjuvants (ASIA syndrome) manifesting as subacute thyroiditis. J Endocrinol Invest. 2022;45:465–7.PubMedCrossRef
6.
go back to reference Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12: 714170.PubMedPubMedCentralCrossRef Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12: 714170.PubMedPubMedCentralCrossRef
7.
go back to reference Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407–16.PubMedPubMedCentralCrossRef Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407–16.PubMedPubMedCentralCrossRef
8.
go back to reference Rosenberg ES, Dorabawila V, Easton D, et al. COVID-19 vaccine effectiveness by product and timing in New York State 2021. N Engl J Med. 2022;386:116–27.PubMedCrossRef Rosenberg ES, Dorabawila V, Easton D, et al. COVID-19 vaccine effectiveness by product and timing in New York State 2021. N Engl J Med. 2022;386:116–27.PubMedCrossRef
9.
go back to reference Pomara C, Sessa F, Ciaccio M, Dieli F, Esposito M, et al. COVID-19 vaccine and death: causality algorithm according to the WHO Eligibility Diagnosis. Diagnostics (Basel). 2021;11:955.PubMedCrossRef Pomara C, Sessa F, Ciaccio M, Dieli F, Esposito M, et al. COVID-19 vaccine and death: causality algorithm according to the WHO Eligibility Diagnosis. Diagnostics (Basel). 2021;11:955.PubMedCrossRef
10.
go back to reference Wang L, Wang FS, Gershwin ME, Gershwin E. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369–95.PubMedCrossRef Wang L, Wang FS, Gershwin ME, Gershwin E. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369–95.PubMedCrossRef
11.
go back to reference Pellegrino P, Carnovale C, Pozzi M, Antoniazzi S, Perrone V, Salvati D, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev. 2014;13:736–41.PubMedCrossRef Pellegrino P, Carnovale C, Pozzi M, Antoniazzi S, Perrone V, Salvati D, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev. 2014;13:736–41.PubMedCrossRef
12.
13.
go back to reference Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet. 2003;15(362):1659–66.CrossRef Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet. 2003;15(362):1659–66.CrossRef
14.
go back to reference Ruggeri RM, Giovanellla L, Campennì A. SARS-CoV-2 vaccine may trigger thyroid autoimmunity: real-life experience and review of the literature. J Endocrinol Invest. 2022;45:2283–9.PubMedPubMedCentralCrossRef Ruggeri RM, Giovanellla L, Campennì A. SARS-CoV-2 vaccine may trigger thyroid autoimmunity: real-life experience and review of the literature. J Endocrinol Invest. 2022;45:2283–9.PubMedPubMedCentralCrossRef
15.
go back to reference Rotondi M, Coperchini F, Ricci G, Denegri M, Croce L, Ngnitejeu ST, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. J Endocrinol Invest. 2021;44:1085–90.PubMedCrossRef Rotondi M, Coperchini F, Ricci G, Denegri M, Croce L, Ngnitejeu ST, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. J Endocrinol Invest. 2021;44:1085–90.PubMedCrossRef
16.
go back to reference Sakurai K, Narita D, Saito N, Ueno T, Sato R, et al. Type 1 diabetes mellitus following COVID-19 RNA-based vaccine. J Diabetes Investig. 2022;13:1290–2.PubMedPubMedCentralCrossRef Sakurai K, Narita D, Saito N, Ueno T, Sato R, et al. Type 1 diabetes mellitus following COVID-19 RNA-based vaccine. J Diabetes Investig. 2022;13:1290–2.PubMedPubMedCentralCrossRef
17.
go back to reference Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008;57:1084–92.PubMedCrossRef Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008;57:1084–92.PubMedCrossRef
18.
go back to reference Abdul-Rasoul M, Habib H, Al-Khouly M. ‘The honeymoon phase’ in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes. 2006;7:101–7.PubMedCrossRef Abdul-Rasoul M, Habib H, Al-Khouly M. ‘The honeymoon phase’ in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes. 2006;7:101–7.PubMedCrossRef
22.
go back to reference Li Z, Guo J, Bi L. Role of the NLRP3 inflammasome in autoimmune diseases. Biomed Pharmacother. 2020;130: 110542.PubMedCrossRef Li Z, Guo J, Bi L. Role of the NLRP3 inflammasome in autoimmune diseases. Biomed Pharmacother. 2020;130: 110542.PubMedCrossRef
23.
go back to reference Samuel I, Hubert M. Innate viral sensor MDA5 and coxsackievirus interplay in type 1 diabetes development. Microorganisms. 2020;8:993.CrossRef Samuel I, Hubert M. Innate viral sensor MDA5 and coxsackievirus interplay in type 1 diabetes development. Microorganisms. 2020;8:993.CrossRef
24.
go back to reference Sasaki K, Morioka T, Okada N, Natsuki Y, Kakutani Y, Ochi A, et al. New-onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination: a case report. J Diabetes Invest. 2022;13:1286–9.CrossRef Sasaki K, Morioka T, Okada N, Natsuki Y, Kakutani Y, Ochi A, et al. New-onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination: a case report. J Diabetes Invest. 2022;13:1286–9.CrossRef
25.
go back to reference Yano M, Morioka T, Natsuki Y, Sasaki K, Kakutani Y, Ochi A, et al. New-onset type 1 diabetes after COVID-19 mRNA vaccination. Intern Med. 2022;61:1197–200.PubMedPubMedCentralCrossRef Yano M, Morioka T, Natsuki Y, Sasaki K, Kakutani Y, Ochi A, et al. New-onset type 1 diabetes after COVID-19 mRNA vaccination. Intern Med. 2022;61:1197–200.PubMedPubMedCentralCrossRef
26.
go back to reference Sasaki H, Itoh A, Watanabe Y, Nakajima Y, Saisho Y, Irie J, et al. Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: a case report. J Diabetes Invest. 2022;13:1105–8.CrossRef Sasaki H, Itoh A, Watanabe Y, Nakajima Y, Saisho Y, Irie J, et al. Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: a case report. J Diabetes Invest. 2022;13:1105–8.CrossRef
27.
go back to reference Sato T, Kodama S, Kaneko K, Imai J, Katagiri H. Type 1 diabetes mellitus associated with nivolumab after second SARS-CoV-2 vaccination. Jpn Emerg Infect Dis. 2022;28:1518–20.CrossRef Sato T, Kodama S, Kaneko K, Imai J, Katagiri H. Type 1 diabetes mellitus associated with nivolumab after second SARS-CoV-2 vaccination. Jpn Emerg Infect Dis. 2022;28:1518–20.CrossRef
29.
go back to reference Bleve E, Venditti V, Lenzi A, Morano S, Filardi T. COVID-19 vaccine and autoimmune diabetes in adults: report of two cases. J Endocrinol Invest. 2022;45:1269–70.PubMedPubMedCentralCrossRef Bleve E, Venditti V, Lenzi A, Morano S, Filardi T. COVID-19 vaccine and autoimmune diabetes in adults: report of two cases. J Endocrinol Invest. 2022;45:1269–70.PubMedPubMedCentralCrossRef
30.
go back to reference Patrizio A, Ferrari SM, Antonelli A, Fallahi P. A case of Graves’ disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J Autoimmun. 2021;125: 102738.PubMedPubMedCentralCrossRef Patrizio A, Ferrari SM, Antonelli A, Fallahi P. A case of Graves’ disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J Autoimmun. 2021;125: 102738.PubMedPubMedCentralCrossRef
32.
go back to reference Ohuchi K, Amagai R, Tamabuchi E, Kambayashi Y, Fujimura T. Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy. J Dermatol. 2022;49:e167–8.PubMedCrossRef Ohuchi K, Amagai R, Tamabuchi E, Kambayashi Y, Fujimura T. Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy. J Dermatol. 2022;49:e167–8.PubMedCrossRef
33.
go back to reference Moon H, Suh S, Park MK. Adult-onset type 1 diabetes development following COVID-19 mRNA vaccination. J Korean Med Sci. 2023;38: e12.PubMedCrossRef Moon H, Suh S, Park MK. Adult-onset type 1 diabetes development following COVID-19 mRNA vaccination. J Korean Med Sci. 2023;38: e12.PubMedCrossRef
34.
go back to reference Tanaka S, Endo T, Aida K, Shimura H, Yokomori N, Kaneshige M, et al. Distinct diagnostic criteria of fulminant type 1 diabetes based on serum C-peptide response and HbA1c levels at onset. Diabetes Care. 2004;27:1936–41.PubMedCrossRef Tanaka S, Endo T, Aida K, Shimura H, Yokomori N, Kaneshige M, et al. Distinct diagnostic criteria of fulminant type 1 diabetes based on serum C-peptide response and HbA1c levels at onset. Diabetes Care. 2004;27:1936–41.PubMedCrossRef
35.
go back to reference Burrack AL, Martinov T, Fife BT. T cell-mediated beta cell destruction: autoimmunity and alloimmunity in the context of type 1 diabetes. Front Endocrinol (Lausanne). 2017;8:343.PubMedCrossRef Burrack AL, Martinov T, Fife BT. T cell-mediated beta cell destruction: autoimmunity and alloimmunity in the context of type 1 diabetes. Front Endocrinol (Lausanne). 2017;8:343.PubMedCrossRef
36.
go back to reference Nemoto M, Sugisawa H, Nishimura R, et al. Factors affecting the honeymoon period in adult-onset Japanese type 1 diabetes. J Jpn Diab Soc. 2011;54:98–102. Nemoto M, Sugisawa H, Nishimura R, et al. Factors affecting the honeymoon period in adult-onset Japanese type 1 diabetes. J Jpn Diab Soc. 2011;54:98–102.
37.
go back to reference Chang L, Mo-Ning G, Zhonglin C, Zhong X, Guanjie C. Association between Covid-19 vaccination and incidence of type 1 diabetes in China: evidence from 14.14 million registered residents between 2007 and 2021. Diabetes Res Clin Pract. 2023;201:110723.CrossRef Chang L, Mo-Ning G, Zhonglin C, Zhong X, Guanjie C. Association between Covid-19 vaccination and incidence of type 1 diabetes in China: evidence from 14.14 million registered residents between 2007 and 2021. Diabetes Res Clin Pract. 2023;201:110723.CrossRef
38.
go back to reference Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009;52:2513–21.PubMedCrossRef Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009;52:2513–21.PubMedCrossRef
39.
go back to reference Imagawa A, Hanafusa T. Fulminant type 1 diabetes—east and west. J Clin Endocrinol Metab. 2023;108:e1473–8.PubMedCrossRef Imagawa A, Hanafusa T. Fulminant type 1 diabetes—east and west. J Clin Endocrinol Metab. 2023;108:e1473–8.PubMedCrossRef
40.
go back to reference Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T. Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Invest. 2012;3:62–9.CrossRef Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T. Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Invest. 2012;3:62–9.CrossRef
41.
Metadata
Title
Type 1 diabetes mellitus following COVID-19 vaccination: a report of two cases and review of literature
Authors
Shota Mochizuki
Junnosuke Miura
Kiwako Ucida
Ryo Kubota
Hirona Fujikawa
Satoshi Takagi
Naoshi Yoshida
Sachiko Ootake
Chika Fujimori
Akihito Shinohara
Junji Tanaka
Tetsuya Babazono
Publication date
29-02-2024
Publisher
Springer Nature Singapore
Published in
Diabetology International
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-024-00695-9
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.